Articles

Tucatinib Plus Trastuzumab Plus Capecitabine Is Efficacious After Trastuzumab Deruxtecan Exposure in HER2-Positive MBC

Interim results from the Asia cohort of the HER2 REAL study found heterogeneous treatment patterns among patients with HER2-positive unresectable locally advanced or metastatic breast cancer progressing on HER2-directed therapies. Read More ›

PERMEATE: Updated Results of Pyrotinib Plus Capecitabine in Patients With HER2-Positive MBC and Brain Metastases

Results of a large multicenter retrospective study confirmed that tucatinib in combination with trastuzumab and capecitabine was efficacious in patients with HER2-positive metastatic breast cancer with previous exposure to trastuzumab deruxtecan. Read More ›

HER2CLIMB-05: Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2-Positive LA/MBC

Updated results of the phase 2 PERMEATE trial confirmed that pyrotinib plus capecitabine provided long-term survival benefit in patients with HER2-positive metastatic breast cancer and brain metastases. Read More ›

PRECIOUS: Pertuzumab Re-treatment Improved OS in HER2-Positive LA/MBC in a Phase 3 Trial, but Did Treatment Imbalances Impact the Outcomes?

The phase 3 HER2CLIMB-05 trial is evaluating tucatinib plus trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive locally advanced or metastatic breast cancer. Read More ›

Updated results of the phase 3 randomized PRECIOUS trial demonstrated that dual HER2 blockade with pertuzumab re-treatment in combination with trastuzumab plus chemotherapy led to significant overall survival improvement compared with trastuzumab plus chemotherapy in patients previously treated with pertuzumab-containing regimens for HER2-positive locally advanced/metastatic breast cancer, but potential imbalances in chemotherapy during and after the study treatment period may have impacted the results. Read More ›

Emerging Treatment Landscape for Multiple Myeloma

New targets and innovative therapies for multiple myeloma were highlighted in two sessions presented at ONS 2023. Read More ›

Nursing Considerations for Select Multiple Myeloma Treatments

Specific factors to be considered are outlined for the management of multiple myeloma treated with certain therapies. Read More ›

Adverse Event Management in Multiple Myeloma

Common treatment-related adverse events and management approaches to multiple myeloma were outlined in three separate sessions at the ONS 2023 Congress. Read More ›

Shared Decision-Making and Self-Management of Cancer Through Patient Empowerment and Education

Approaches to help build healthcare professional and patient relationships and considerations for symptom management by patients with multiple myeloma are discussed. Read More ›

Health Disparities in Marginalized Patient Populations with Cancer